Relationships between the proton nuclear magnetic resonance properties of plasma lipoproteins and cancer

1991 ◽  
Vol 37 (3) ◽  
pp. 369-376 ◽  
Author(s):  
J D Otvos ◽  
E J Jeyarajah ◽  
L W Hayes ◽  
D S Freedman ◽  
N A Janjan ◽  
...  
Keyword(s):  
Nuclear Magnetic Resonance ◽  
Magnetic Resonance ◽  
Plasma Lipids ◽  
Plasma Lipoproteins ◽  
Proton Nuclear Magnetic Resonance ◽  
High Density Lipoproteins ◽  
Cancer Group ◽  
Lipoprotein Lipid ◽  
The Difference ◽  
Nuclear Magnetic

Abstract We conducted a comprehensive investigation of the origin of nuclear magnetic resonance (NMR) lineshape variability of plasma lipids among healthy individuals and those with cancer. The methyl and methylene resonances of lipid in human plasma, whose linewidths have been reported to correlate with the presence of malignancy, are composed of the overlapping resonances of "mobile" protons from the major lipoproteins (very-low-, low-, and high-density lipoproteins). We tested two hypotheses for the origin of the narrower plasma linewidths observed for cancer patients: (a) malignancy-associated differences in the spectral properties (chemical shift, lineshape) of one or more of the lipoproteins, and (b) differences in the fraction of lipoprotein lipid giving rise to detectable NMR signal. Analysis of the concentrations of lipoprotein lipid and of 500 MHz NMR spectra of the lipoprotein constituents in greater than 100 plasma samples failed to provide support for either hypothesis. Although linewidths were found to be significantly narrower for the cancer group, the difference is entirely attributable to differences in the concentrations of the lipoproteins.

Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy

1991 ◽  
Vol 37 (3) ◽  
pp. 377-386 ◽  
Author(s):  
J D Otvos ◽  
E J Jeyarajah ◽  
D W Bennett
Keyword(s):  
Nuclear Magnetic Resonance ◽  
Magnetic Resonance ◽  
Curve Fitting ◽  
Plasma Lipoproteins ◽  
Proton Nuclear Magnetic Resonance ◽  
High Density Lipoproteins ◽  
Resonance Spectroscopy ◽  
Single Spectrum ◽  
Moderate Magnetic Field ◽  
Nuclear Magnetic

Abstract A new analytical procedure for quantifying plasma lipoproteins by proton nuclear magnetic resonance (NMR) spectroscopy has been developed that potentially offers significant advantages over existing clinical methods used for assessing risk of coronary heart disease. Analysis of a single spectrum of a nonfasting plasma sample, acquired simply and rapidly at moderate magnetic field strength (250 MHz), yields a complete profile of lipoprotein concentrations: chylomicrons and very-low-, low-, and high-density lipoproteins. The method is based on curve-fitting (spectral deconvolution) of the plasma methyl lipid resonance envelope, the amplitude and shape of which depend directly on the amplitudes of the superimposed methyl resonances of the lipoprotein components. A linear least-squares curve-fitting algorithm was developed to efficiently extract the signal amplitudes (concentrations) of the lipoproteins from the plasma spectrum. These signal amplitudes correlate well with lipoprotein concentrations determined by triglyceride and cholesterol measurements.

Development of a Proton Nuclear Magnetic Resonance Spectroscopic Method for Determining Plasma Lipoprotein Concentrations and Subspecies Distributions from a Single, Rapid Measurement

1992 ◽  
Vol 38 (9) ◽  
pp. 1632-1638 ◽  
Author(s):  
J D Otvos ◽  
E J Jeyarajah ◽  
D W Bennett ◽  
R M Krauss
Keyword(s):  
Nuclear Magnetic Resonance ◽  
Magnetic Resonance ◽  
Spectroscopic Method ◽  
Plasma Lipid ◽  
Plasma Lipoproteins ◽  
Proton Nuclear Magnetic Resonance ◽  
Low Density ◽  
Lipoprotein Class ◽  
Varied Composition ◽  
Nuclear Magnetic

Abstract We are developing a method for quantifying plasma lipoproteins by proton nuclear magnetic resonance (NMR) spectroscopy that offers advantages over existing clinical methods. We showed that the major lipoproteins have distinct NMR properties sufficient to permit their concentrations to be extracted from a computer lineshape analysis of the plasma lipid methyl resonance envelope (Clin Chem 1991; 37:377-86). We have now discovered that the spectra of the subspecies within each lipoprotein class are different enough to influence the composite spectrum of that class and hence the spectrum of whole plasma. By including spectra representative of these subspecies as additional components in the lineshape-fitting analysis, a complete concentration profile of very-low-density, low-density (LDL), and high-density (HDL) lipoproteins plus the subspecies distributions within these classes can be simultaneously generated. A pilot study of 30 plasma samples of widely varied composition demonstrated good agreement between NMR-derived values and lipoprotein lipid concentrations and LDL and HDL subspecies distributions determined by gradient-gel electrophoresis.

Failure of 1H nuclear magnetic resonance spectroscopy of blood plasma to detect malignancy.

1990 ◽  
Vol 8 (5) ◽  
pp. 906-910 ◽  
Author(s):  
P Okunieff ◽  
M D Greenberg ◽  
A Zietman ◽  
J Kahn ◽  
S Westgate ◽  
...  
Keyword(s):  
Nuclear Magnetic Resonance ◽  
Magnetic Resonance ◽  
Malignant Tumors ◽  
Massachusetts General Hospital ◽  
False Negative ◽  
Plasma Lipoproteins ◽  
Proton Nuclear Magnetic Resonance ◽  
Resonance Spectroscopy ◽  
Line Widths ◽  
Nuclear Magnetic

Water-suppressed proton nuclear magnetic resonance (NMR) of plasma was proposed as a technique for detecting malignant tumors. In that analysis, bloods drawn from cancer patients at the Beth Israel Hospital (BIH; Boston, MA), were easily distinguished from normal subjects by measuring and averaging the proton NMR methyl and methylene line widths of plasma lipoproteins. We collected blood at the Massachusetts General Hospital (MGH), including from normal controls, patients with untreated and treated malignant tumors, and patients with nontumor diseases. The plasma NMR analyses were carried out blind. The code was not broken until all patient charts and pathology records were reviewed, plasma analyses were completed, and patients had been divided into appropriate clinical groups. Analysis of these data showed no differences between the means of the study groups (false-positive and false-negative frequencies 46% and 57%, respectively). An inverse correlation of methyl/methylene line widths with age (P less than .01), and a correlation with nitrate-requiring cardiovascular disease (P less than .05) was, however, evident. This test cannot be validly used to detect malignancy.

scholarly journals N-[7-Chloro-4-[4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl] quinoline]-acetamide

Molbank ◽  
10.3390/m1213 ◽  
2021 ◽  
Vol 2021 (2) ◽  
pp. M1213
Author(s):  
Paolo Coghi ◽  
Jerome P. L. Ng ◽  
Ali Adnan Nasim ◽  
Vincent Kam Wai Wong
Keyword(s):  
Nuclear Magnetic Resonance ◽  
Magnetic Resonance ◽  
Quantum Coherence ◽  
Biologically Active ◽  
Proton Nuclear Magnetic Resonance ◽  
Dipolar Cycloaddition ◽  
Heteronuclear Single Quantum Coherence ◽  
Pharmacokinetic Properties ◽  
Nuclear Magnetic

The 1,2,3-triazole is a well-known biologically active pharmacophore constructed by the copper-catalyzed azide–alkyne cycloaddition. We herein reported the synthesis of 4-amino-7-chloro-based [1,2,3]-triazole hybrids via Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition of 4-azido-7-chloroquinoline with an alkyne derivative of acetaminophen. The compound was fully characterized by Fourier-transform infrared (FTIR), proton nuclear magnetic resonance (1H-NMR), carbon-13 nuclear magnetic resonance (13C-NMR), heteronuclear single quantum coherence (HSQC), ultraviolet (UV) and high-resolution mass spectroscopies (HRMS). This compound was screened in vitro with different normal and cancer cell lines. The drug likeness of the compound was also investigated by predicting its pharmacokinetic properties.

Sign in / Sign up

Export Citation Format

Share Document